Though retrospective, the findings provide ‘compelling’ evidence that GLP-1 receptor agonists may help prevent development ...

The use of GLP-1s among patients with type 2 diabetes appeared associated with significantly reduced risk for certain ...

With GLP-1 shortage officially over, patients who relied on compounded copies have only bad options to choose from ...

The benefit of GLP-1 therapy couldn’t be explained by weight loss, suggesting that some pleiotropic effects may be at work.

Mukhopadhyay took Mounjaro, an antidiabetic medication also used for weight loss, and saw dramatic results—losing 15 percent ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are a group of drugs used to treat type 2 diabetes and sometimes obesity. GLP-1 RAs are very effective at lowering blood sugar levels.

A new study from Rutgers University links higher body dissatisfaction, BMI, and maladaptive weight loss behaviors with ...

Nationally representative survey data reveals that glucagon-like peptide 1 receptor agonists (GLP-1 RAs) use for obesity treatment more than tripled among US adults without diabetes between 2018 and ...

The FDA accepted Novo Nordisk's NDA for an oral formulation of Wegovy. The agency is expected to release its verdict on the ...

Yet the disparities by sex, race/ethnicity, and location pale in comparison to a striking overall lack of adoption.

Pharmaceutical giant Eli Lilly alleges the companies are selling illegal off-brand versions of its best-selling diabetes and ...

A new study from the Karolinska Institutet in Sweden has found that a common type of diabetes medicine might also help ...